Tty Biopharm
Tty Biopharm Corporation, commonly referred to as Tty Biopharm, is a prominent player in the biopharmaceutical industry, headquartered in Taiwan (TW). Founded in 1966, the company has established itself as a leader in the development and manufacturing of innovative pharmaceuticals, particularly in oncology and other therapeutic areas. With a strong presence in both domestic and international markets, Tty Biopharm is renowned for its commitment to quality and research-driven solutions. The company’s core offerings include a diverse range of generic and proprietary medications, distinguished by their efficacy and safety profiles. Notable achievements include strategic partnerships and a robust pipeline of products that cater to unmet medical needs, solidifying Tty Biopharm's position as a trusted name in the biopharmaceutical landscape.
DitchCarbon Score
How does Tty Biopharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tty Biopharm's score of 40 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Tty Biopharm's reported carbon emissions
In 2023, Tty Biopharm reported total carbon emissions of approximately 9,484,000 kg CO2e. This figure includes 1,700,220 kg CO2e from Scope 1 emissions, 8,488,800 kg CO2e from Scope 2 emissions, and 2,549,520 kg CO2e from Scope 3 emissions. Notably, the Scope 3 emissions include 2,001,170 kg CO2e attributed to purchased goods and services. Over the years, Tty Biopharm has shown fluctuations in its emissions. For instance, in 2022, total emissions were about 8,836,000 kg CO2e, with Scope 1 at 1,535,320 kg CO2e and Scope 2 at 8,232,490 kg CO2e. The company has not disclosed specific reduction targets or initiatives, nor has it committed to any climate pledges or SBTi (Science Based Targets initiative) reduction targets. The emissions data indicates a growing trend in total emissions, reflecting the company's increasing revenue, which reached approximately 179,696,519 USD in 2023. Despite the lack of formal reduction commitments, Tty Biopharm's emissions profile highlights the importance of addressing carbon footprints in the biopharmaceutical industry, particularly as global climate concerns intensify.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 1,219,000 | 000,000 | 0,000.0 | 000,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 6,845,000 | 0,000,000 | 000,000.0 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 8,065,000 | 0,000,000 | 0,000,000.0 | 00,000.0 | 00,000.0 | 00,000.0 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Tty Biopharm is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
